Illumina Forecasts 2015 Revenues and Announces Four New Products
Illumina also announced that it expects FDA clearance of the NextSeq 500 System later this year or early next year. This year the company plans to launch an integrated solution for HLA typing and an integrated solution for forensics. The next-generation–sequencing (NGS) standards developed by Illumina’s Actionable Genome Consortium (see IBO 9/30/14) will be published shortly.
San Diego, CA 1/12/15; San Francisco, CA 1/12/15; Washington, DC 1/12/15—At the annual JP Morgan Healthcare Conference, Illumina announced that its 2014 revenues grew 20%, following a 32% increase in the fourth quarter to $512 million. The company forecasts 2015 revenues to increase 20% and non-GAAP EPS of $3.12–$3.18. In addition, Illumina announced four new sequencing instruments: the five-unit, $6 million HiSeq X Five system for population genomics; the $740,000 HiSeq 3000 and $900,000 4000 Systems, which are based on the HiSeq X Ten’s patterned flow-cell technology for a lower price-per data point; and the $275,000 NextSeq 550 System, an array scanning-enabled sequencer, whose initial applications will be cytogenetics and prenatal genetic diagnosis.
